Rigel Pharmaceuticals Inc（RIGL）财务数据RIGLRigel Pharmaceuticals Inc

Evaluating the bottom line, Rigel Pharmaceuticals, Inc. maintains a gross margin of 89.17%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at 29.95%, while the net margin is 21.97%. These profitability ratios, combined with a Return on Equity (ROE) of 126.90%, provide a clear picture of how effectively RIGL converts its operational activities into shareholder value.

In the context of the broader market, RIGL competes directly with industry leaders such as ACRS and TBPH. With a market capitalization of $875.34M, it holds a significant position in the sector. When comparing efficiency, RIGL's gross margin of 89.17% stands against ACRS's 10.80% and TBPH's 100.00%. Such benchmarking helps identify whether Rigel Pharmaceuticals, Inc. is trading at a premium or discount relative to its financial performance.

Rigel has shown strong financial performance with total revenues of $78.7 million in Q2 2026, and a gross margin of 89.17% in the same quarter, indicating efficient cost management and strong profitability.